---
figid: PMC4260046__atm-02-12-122-f1
figlink: /pmc/articles/PMC4260046/figure/f1/
number: F1
caption: Schematic of the binding sites on human epidermal growth factor receptor
  2 (HER2) for FDA-approved HER2-directed therapies. HER2 is a transmembrane receptor.
  Activation of HER2 results in cell signaling through the MAPK (RAS, RAF, MEK, and
  ERK) pathway and PI3K/Akt/mTOR pathways, leading to cellular proliferation. Trastuzumab
  and T-DM1 binds to the juxtamembrane domain of HER and inhibits cell signaling.
  T-DM1 is then endocytosed and DM-1 is released within the cell, where it can exert
  its cytotoxic effect via inhibiting microtubule function. In contrast pertuzumab
  binds domain II of the extracellular domain of HER2, preventing receptor heterodimerization
  with HER1, HER3, and HER4, and cell signaling. The tyrosine kinase inhibitor lapatinib
  binds the intracellular adenosine triphosphate binding domain of HER1 and HER2 and
  results in inhibition of cell signaling.
pmcid: PMC4260046
papertitle: Recent advances in the development of anti-HER2 antibodies and antibody-drug
  conjugates.
reftext: Deborah J.L. Wong, et al. Ann Transl Med. 2014 Dec;2(12):122.
pmc_ranked_result_index: '84056'
pathway_score: 0.976671
filename: atm-02-12-122-f1.jpg
figtitle: The binding sites on human epidermal growth factor receptor 2 (HER2) for
  FDA-approved HER2-directed therapies
year: '2014'
organisms: Homo sapiens
ndex: 4cd61e8f-deb1-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4260046__atm-02-12-122-f1.html
  '@type': Dataset
  description: Schematic of the binding sites on human epidermal growth factor receptor
    2 (HER2) for FDA-approved HER2-directed therapies. HER2 is a transmembrane receptor.
    Activation of HER2 results in cell signaling through the MAPK (RAS, RAF, MEK,
    and ERK) pathway and PI3K/Akt/mTOR pathways, leading to cellular proliferation.
    Trastuzumab and T-DM1 binds to the juxtamembrane domain of HER and inhibits cell
    signaling. T-DM1 is then endocytosed and DM-1 is released within the cell, where
    it can exert its cytotoxic effect via inhibiting microtubule function. In contrast
    pertuzumab binds domain II of the extracellular domain of HER2, preventing receptor
    heterodimerization with HER1, HER3, and HER4, and cell signaling. The tyrosine
    kinase inhibitor lapatinib binds the intracellular adenosine triphosphate binding
    domain of HER1 and HER2 and results in inhibition of cell signaling.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - MAPK1
  - MTOR
  - MAP2K1
  - MAPK3
  - PIK3R5
  - MAP2K2
  - ERBB4
  - PIK3CG
  - ERBB3
  - AKT2
  - PIK3R4
  - HRAS
  - PIK3R6
  - RAF1
  - AKT3
  - BRAF
  - PIK3CD
  - PIK3R3
  - ARAF
  - KRAS
  - NRAS
  - PIK3CB
  - AKT1
  - PIK3CA
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: Her2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: mTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: Her4
  symbol: HER4
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB4
  entrez: '2066'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: Her3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4260046__F1
redirect_from: /figures/PMC4260046__F1
figtype: Figure
---
